Rodman & Renshaw

Rodman & Renshaw maintains its Buy rating on Just Energy Group Inc (NYSE: JE), saying that the stock is "undervalued" as the company is poised to benefit from its "strategy of allowing lower margin customer attrition." Why Buy? During the year ended March 31, 2016, the company lost about 166,...

Rodman & Renshaw's Raghuram Selvaraju reiterated his Buy position on Synergy Pharmaceuticals Inc (NASDAQ: SGYP) with a price target of $15.00. The rating reiteration comes after further Plecanatide Phase 3 data was reported, showing positive results. The new data "emphasizes what we view as the...

Rodman & Renshaw's Raghuram Selvaraju downgraded Nanosphere, Inc. (NASDAQ: NSPH) from Buy to Neutral, while decreasing the price target from $2.00 to $1.35. The rating change came after Luminex Corporation (NASDAQ: LMNX) announced it was acquiring Nanosphere for $1.35 a share in an all-cash...

Rodman & Renshaw has started Presbia PLC (NASDAQ: LENS) with a Buy rating and $14 price target, saying the company is "an unsung company with an intriguingly positioned device in the attractive ophthalmics domain." Presbia makes the Flexivue Microlens for presbyopia (nearsightedness). The...

Rodman & Renshaw analyst Raghuram Selvaraju believes LabStyle Innovations Corp (NASDAQ: DRIO) could more than double in a year from the current levels. The brokerage initiated coverage with a rating of Buy and a price target of $12.00 on valuation. The optimism was due to the development of an...

Like many small-cap biotech stocks, Synergy Pharmaceuticals Inc (NASDAQ: SGYP) is no stranger to the rumor mill. StreetInsider reported the company was exploring a sale on April 8, sending shares 8 percent higher. Bloomberg reported a similar rumor in March 2015, also yielding no follow-through...

The Street Sweeper's Sonya Colberg published a scathing short thesis on Bio-Path Holdings Inc (NASDAQ: BPTH), a clinical-stage biotechnology company that focuses on developing drugs to fight cancer. Colberg's main criticism of the company is the fact that it "spent six years...

On April 25, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced that the former CEO of Perrigo Company plc Ordinary Shares (NYSE: PRGO), Joseph Papa, would replace the outgoing Mike Pearson as chairman and CEO. Rodman & Renshaw’s Raghuram Selvaraju reiterated a Buy rating on Valeant...

On March 30, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced that it had started a process for an amendment and waiver to its existing credit facility. Rodman & Renshaw’s Raghuram Selvaraju reiterated a Buy rating on the company, with a price target of $118. Waiver And...

Raghuram Selvaraju of Rodman & Renshaw reiterated his bullish stance on Valeant Pharmaceuticals Intl Inc (NYSE: VRX), a day after the company said its longtime CEO, Mike Pearson, would be stepping down and that he would continue to stay at the helm until his successor is identified....